A. Reches

Efficacy, Tolerability and Safety of Oral Eletriptan and Ergotamine plus Caffeine (Cafergot®) in the Acute Treatment of Migraine: A Multicentre, Randomised, Double-Blind, Placebo-Controlled Comparison

H. Diener, T. Steiner, D. Pitei, 2002, European Neurology.

Introducing a novel approach of network oriented analysis of ERPs, demonstrated on adult attention deficit hyperactivity disorder

A. Geva, H. Pratt, J. Aharon-Peretz, 2012, Clinical Neurophysiology.

Chronic dopa feeding of mice

J. Bhawan, A. Reches, Stanley Fahri, 1982, Neurology.

Effect of nitecapone (OR-462) on the pharmacokinetics of levodopa and 3-O-methyldopa formation in cynomolgus monkeys.

J. Cedarbaum, M. Guttman, G. Léger, 1990, Clinical neuropharmacology.

3‐O‐methyldopa administration does not alter fluorodopa transport into the brain

Alan C. Evans, W. Woodward, A. Gjedde, 1992, Annals of neurology.

Efficacy, tolerability and safety of oral eletriptan and ergotamine plus caffeine (Cafergot) in the acute treatment of migraine: a multicentre, randomised, double-blind, placebo-controlled comparison.

H. Diener, T. Steiner, D. Pitei, 2003, European neurology.

Administration of the new COMT inhibitor OR‐611 increases striatal uptake of fluorodopa

Alan C. Evans, A. Gjedde, J. Cedarbaum, 1993, Movement disorders : official journal of the Movement Disorder Society.

Tumors producing chronic hyperprolactinemia do not alter [3H]spiperone binding and dopamine turnover in the corpus striatum of the female rat.

M. Cronin, R. Macleod, I. Login, 1983, European journal of pharmacology.